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 Original Research Article 
Development and characterization of mucoadhesive patches for buccal delivery of 
pregabalin 
Abstract: 
Pregabalin is a structural analogue of the inhibitory neurotransmitter γ-amino butyric acid 
(GABA) having short half-life (5-6 hrs) and is used in the management of epilepsy. The aim of 
this study was to prepare a buccal patch containing Pregabalin by the means of solvent casting 
method. Six formulations were prepared using different ratio of polymers including HPMC 
K4M, Eudragit RL, and PVP K30. Since buccal mucosa is relatively permeable with rich blood 
supply and acts as an excellent site for the absorption of drugs so, it is an attractive alternate to 
other conventional methods of systemic drug administration. Franz diffusion cell with 
commercially available dialysis membrane was used for the in-vitro diffusion study of buccal 
patches for duration of 12 hrs. Kinetics and mechanism of drug release from all formulation was 
evaluated on the basis of zero order, first order, Hixon-Crowell, Higuchi equation and Peppas 
model. Based on different parameters i.e. folding endurance, drug content, moisture absorption, 
moisture loss, water vapor transmission rate in-vitro release study buccal patches of batch F4 
(HPMC K4M & Eudragit RL 100) was found to an optimum formulation. 
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Introduction: 
Buccal delivery refers to a topical route of administration by whichdrugs held or applied in the 
buccal area, diffuse through the oral mucosa and enter directly into the systemic circulation. 
Dosage form retained at the site of action by intimate contact
1
. The buccal mucosa has rich blood 
supply, easy accessibility and is relativelypermeable and provides affluent blood supply, better 
bioavailability by avoiding first pass metabolism of drugs and a more rapid onset of action. 
Bioadhesion is a phenomenon of interfacial molecular attractive forces in which two materials, 
one of which is natural in origin, are held mutually for extensive periods of time by means of 
interfacial forces for a longer duration
2
. Mucoadhesion is commonly defined as the adhesion 
between two materials, at least one of which is a mucosal surface. Buccal drug delivery is well 
accepted by patients because of possibility of self-medication i.e. comfortable application and 
rapidly termination of dosage form whenever needed
3
.  
Pregabalin is a structural analogue of the inhibitory neurotransmitter γ-amino butyric acid 
(GABA)
4
. It is an oral antiepileptic drug used in the management of epilepsy. Pregabalin has 
been studied for treatment of different disorders, includingmonotherapy in refractory partial 
seizures, diabetic neuropathy, surgical dental pain and other pain syndromes, postherpetic 
neuralgia, and social anxiety disorders
5,6
. 
All these properties make it an ideal candidate to develop a novel dosage form. Keeping these 
factors, in present study bioadhesive patches of Pregabalin were developed and evaluated in 
order to provide a controlled and predictable release, to avoid frequentadministration and thus to 
increase patient compliance. 
MATERIALS AND METHODS: 
Pregabalin was received  from Swiss Pharma Nigeria. HPMC K4M, and PVP K30 was obtained 
from Divinne Construction and Concrete Expressions Limited, Lagos, Nigeria and Eudragit RL 
from JuNeng Nigeria Limited, Nigeria. All other chemicals were arrangedfrom Barata 
Pharmaceuticals, Rivers State Nigeria. 
 Preparation of mucoadhesive patches 
The mucoadhesive films were prepared by solvent casting method. Polymeric solution of 
different polymers i.e. HPMC K4M, Eudragit RL & PVP K30 was prepared by taking them in 
different ratio ( table-1) by means of distilled water under occasional stirring for 4 hrs. The 
resulting viscous solution was filtered through nylon gauze to remove debris and suspended 
particles.  Propylene glycol was added as permeation enhancer by constant stirring.The resultant 
solution was left overnight at room temperature to ensure a clear, bubble-free solution. The 
solution was poured into a glass petri dish. It was kept for drying to form films. Dried films were 
slowly removed from the petri plateand cut into appropriate size. Prepared film stored in a 
desiccator
7
. 
Table-1: Compositions of the Pregabalin buccal films 
S.N. Ingredients F1 F2 F3 F4 F5 F6 
1.  Pregabalin (mg) 50 50 50 50 50 50 
2.  HPMC K4M(mg) 100 - 150 200 - - 
3.  Eudragit RL 
100(mg) 
- 100 - 150 - 200 
4.  PVP K30 100 150 - - - 200 
5.  Propylene glycol 
(ml) 
2.5 2.5 2.5 2.5 200 - 
 
Characterization and evaluation of Mucoadhesive film 
1. Measurement of weight variation and thickness:  
The thickness of the Pregabalin buccal patches was assessed at six different points of the patch 
using thickness gauze (Mitutoyo, Japan). For each formulation, three randomlyselected patches 
were used and the average weights were calculated8. 
2. Measurement of Folding Endurance:  
Folding endurance of Pregabalin buccal patches determined by repeatedly folding one film at the 
same place up to 200 times till it broke or folded, which is consideredsatisfactory to reveal good 
patch properties
9
.  
3. Content Uniformity:  
To determine content uniformity, Pregabalin buccal patches were taken at different locations of 
the prepared film and these films were dissolved in 100mL of pH 6.8 phosphatebuffer solution. 
The solution was centrifuged at 3000 rpm for 15 min. The supernatant was taken and absorbance 
was noted spectrophotometrically at 276 nm10. 
4. Moisture content: 
The Pregabalin buccal patches were weighed accurately and kept in desiccators containing 
anhydrous calcium chloride. After three days, the patches were taken out and weighed
11
. The 
moisture content (%) was determined by calculating moisture loss using the formula- 
 
4. Percentage Moisture Absorption (PMA): 
The percentage moisture absorption study of Pregabalinbuccal patches was carried out to check 
the physical stability of the buccal films at high humid conditions. Three 1cm diameter films 
were cut out and weighed accurately. The films were placed in desiccator containing saturated 
solution of aluminium chloride, keeping the humidity inside the desiccator at 79.5 %. After 3 
days the films were removed, weighed and percentagemoisture absorption was calculated12.  
 5. Water Vapour Transmission Rate (WVTR)  
WVTR is defined as the quantity of moisture transmittedthrough unit area of film in unit time. A 
glass bottle was used in the study having length 5cm, with internal diameter of 0.8cm was filled 
with 2g anhydrous calcium chloride and an adhesive spread across its rim. The Pregabalin buccal 
patch was fixed over the adhesive and the assembly was placed in constant humidity chamber, 
prepared using saturated solution of ammonium chloride and maintained at 37±2
0
C. The 
difference in weight after three days was calculated. The vapor transmission rate was obtained as 
follow
13
. 
VTR= (Amount of moisture transmitted)/(Area × Time) 
7. Percent drug content: 
Drug content uniformity was determined by dissolving the Pregabalin buccal patch (10 mm in 
diameter) from each batch by homogenization in 100 ml of an isotonic phosphate buﬀer (pH 6.8) 
for 6 h under occasional shaking. The 5ml solution was taken and diluted with isotonic 
phosphate buﬀer pH 6.8 up to 20 ml, and the resulting solution was filtered through a 0.45 mm 
What man filter paper. Drug content was thendetermined after proper dilution at 276 nm using an 
UV spectrophotometer
14
.  
8. Surface pH: 
Pregabalin buccal patches were left to swell for 1 hour on the surface of the agar plate, the agar 
plate prepared by dissolving 2% (w/v) agar in warmed isotonic phosphate buffer of pH 6.6 under 
stirring and the solution was poured into the petri dish, itwas allowed to stand until it solidified 
to form a gel at room temperature. The surface pH was measured by means of pH paper placed 
on the surface of the swollen patch
15
.  
9. In-vitro diffusion study:  
Franz diffusion cell with commercially available dialysis membranewas used for the in-vitro 
diffusion study of Pregabalin buccal patches for duration of 12 hrs. The receptor compartment 
was filled with phosphate buffer saline, pH 6.8. The patches were applied under occlusion on the 
dialysis membrane fitted between the donor and receptor compartments of the diffusion cell. The 
drug release was performed at 37 ± 0.5°C, at a stirring speed of 50 rpm using a magnetic stirrer. 
Five milliliters of the sample from receptor medium was withdrawn at regular intervals and 
replaced immediately with an equal volume of phosphate buffer.The amount of drug released 
into the receptor medium was measured by means of UV visible spectrophotometer at 276 nm16. 
 
Table-2: Properties of Pregabalin buccal patches 
Code Thickness 
(mm) 
Weight 
(mg) 
Folding 
endurance 
% Drug 
content 
% 
Moisture 
absorption 
% 
Moisture 
loss 
 
WVTR 
(gcm
-2
h
-1
) 
Surface 
pH 
   
F1 0.48±0.25 0.31±0.35 211±1.2 97.41±0.09 12.5±0.48 4.3±0.25 0.358±0.09 6.8 
F2 0.49±0.17 0.38±0.09 232±0.8 96.53±0.11 11.31±0.32 3.8±0.41 0.423±0.13 6.9 
F3 0.52±0.09 0.37±0.07 225±0.5 95.42±0.53 13.27±0.28 5.2±0.09 0.485±0.21 7.0 
F4 0.57±0.08 0.28±0.31 244±0.4 98.32±0.25 9.72±0.15 3.7±0.13 0.511±0.35 7.2 
F5 0.51±0.14 0.25±0.42 243±0.9 91.61±0.58 11.44±0.08 3.6±0.27 0.478±0.44 6.7 
F6 0.49±0.23 0.32±0.51 246±1.4 94.53±0.42 15.38±0.26 4.9±0.32 0.468±0.53 7.1 
 
 
  
Figure 1: Percentage moisture absorption and moisture loss 
 
 
Figure 2: In-vitro diffusion profile of Pregabalin buccal patches 
Table 3: Statistical analysis of Pregabalin buccal patches 
Code Zero 
order 
First order Hixon-
Crowell 
Higuchi 
Plot 
Korsmeyer- Peppas 
 R R  R R n 
F1 0.9865 0.7529 0.8325 0.4058 0.9264 1.0231 
F2 0.9547 0.7138 0.8764 0.5037 0.9378 1.1682 
F3 0.8871 0.7262 0.8537 0.4485 0.9152 1.0381 
F4 0.8358 0.7453 0.7928 0.5132 0.8936 0.9934 
F5 0.8549 0.6938 0.7732 0.6028 0.9015 1.1573 
F6 0.8932 0.7621 0.8014 0.7325 0.8632 1.1821 
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 Results and discussion: 
Pregabalin buccal patches in polymers were prepared by solvent casting method. 
Formulated patches were subjected to the preliminary evaluation tests. Patches with any 
imperfections or differing in thickness, weight (or) contentuniformity were excluded from further 
studies. 
The thickness (table 4) of formulated patches varied from 0.48±0.25 to 0.52±0.09 mm. Group F4 
(Eudragit RL 100) have highest thickness while group (F1 HPMC K4M and PVP K30) has 
shown least among all formulations. 
The average weight of patch from each batch ranges from 0.25±0.42 to 0.38±0.09 (table- 1). 
Results indicate that formulations of batch F5 (HPMC K4M) have the least and of batch F4 have 
the highest mass among the different formulations. 
The drug content of films was quite uniform. The average drug content of the films was found to 
be within the range of 91.61– 98.32 % and the low values of standard deviation and coefficient of 
variation indicate uniform distribution of the drug withinthe prepared films. 
The moisture absorption study of patches was done at a relative humidity of 79.5 % for a period 
of three days. The low moisture uptake by all the formulations was observed. The low moisture 
uptake by all the buccal patches can help to retard any hydrolytic degradation, and patches will 
remain stable. Maximum % moisture loss was shown by formulations of batch F3 (5.2±0.09 %). 
Formulation F4 consisting of Eudragit RL 100 has shown highest water vapor transmission rate 
(0.511±0.35 gcm
-2
h
-1
). 
Surface pH of patches was ranges from 6.7 to 7.2 were found around neutral pH neutral pH and 
indicates its compatibility with buccal pH. Films did not show any cracks even after folding for 
more than 200 for all batches. The results indicate that an increase inpolymer concentration 
increased the folding endurance. 
Percentage drug release for the formulations F1, F2, F3, F4, F5 and F6 was found to be 45.32, 
61.2, 76.43, 93.76, 82.48 and 55.62 % respectively in a study of 12 hrs (figure 2). It was 
observed that drug release rate increased by increasing the ratio of HPMC respectively. 
The in vitro release data was applied to various kinetic models to predict the drug release kinetic 
mechanism.  Kinetics and mechanism of drug release from all formulation was evaluated on the 
basis of zero order, first order, Hixon-Crowell, Higuchi equation and Peppas model. Mechanism 
of drug release pattern i.e.diffusion and swelling was confirmed by Higuchi plots. The Higuchi 
plots represent of cumulative percentage drug release versussquare root of time. It was concluded 
that the release of drug from the patches followed the diffusion controlled. 
Conclusion: 
Nowadays, many researchers are working for the progress of the innovative approach of delivery 
of drug to improve the safety, effectiveness and patient compliance. The buccal mucosa has a 
rich blood supply and easily accessible, and suitable for the application of a dosage form to the 
required site. The aim of the present study was to develop a novel unit dosage form of 
Pregabalin. A satisfactory attempt was made to developmucoadhesive buccal patches of 
Pregabalin with different ratio of polymers including HPMC K4M, Eudragit RL, and PVP K30 
by solvent casting method. Based on different parameters i.e. folding endurance, drug content, 
moisture absorption, moisture loss, water vapor transmission rate in-vitro release study buccal 
patches of batch F4 were found to an optimum formulation. 
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